Friday, October 30, 2026

Tech Companies Cut Costs 36% While Margins Rise to 72% in Profitability Pivot

Technology firms are slashing operating expenses while expanding profit margins, marking a strategic shift from growth-focused spending. 10x Genomics reduced quarterly operating costs from $147.9M to $95.0M—a 36% cut—while gross margins climbed from 68% to 72%, even as revenue declined. The pattern extends across the sector, with MongoDB, CrowdStrike, Snowflake, and Marvell reporting Q4 results that prioritize margin expansion over top-line growth.

Tech Companies Cut Costs 36% While Margins Rise to 72% in Profitability Pivot
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

Operating expenses at 10x Genomics dropped from $147.9 million to $95.0 million between quarters while gross margins expanded from 68% to 72%. Revenue fell from $610.8 million to $28 million in the same period, but the company maintained product revenue streams through aggressive cost management.

This represents a broader corporate strategy shift across technology companies. MongoDB beat Q3 revenue guidance on December 3, 2024, and raised full-year projections, signaling that profitability metrics now drive investor confidence more than revenue growth rates.

The fourth quarter of 2024 and first quarter of 2025 brought scheduled earnings from CrowdStrike, Marvell, Snowflake, and Okta. Analysts tracked gross margin trends, operating expense ratios, and EBITDA margins across these releases to measure sector-wide performance against profitability benchmarks.

Companies with decelerating revenue growth now compete on margin expansion rates. The strategy involves three operational changes: reducing headcount and real estate costs, consolidating software tools and cloud infrastructure spending, and focusing R&D budgets on fewer high-margin product lines.

For investors, the metric shift matters. Price-to-sales multiples compressed across the tech sector in 2023-2024. Companies that demonstrate operating leverage—growing profits faster than revenue—now command premium valuations. Those still burning cash for market share face investor pressure.

The profitability focus affects corporate strategy in banking and investment portfolios. Tech allocations now favor companies with positive free cash flow over growth stories. Credit markets price debt differently for profitable versus loss-making tech firms, even within the same revenue scale.

Historical parallels exist. The 2000-2002 dot-com correction forced similar margin discipline. Current conditions differ: interest rates remain higher than the 2010s, making cash flow generation essential for financing operations and growth investments.

The sustainability question centers on whether margin expansion continues once cost-cutting reaches limits. Companies must eventually drive margins through pricing power and operational efficiency rather than expense reduction alone.

In this story · Knowledge Files

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com